Kymera Therapeutics, Inc.
KYMR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815442
In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Kymera Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 210
- +3 vs. Q2 2025
- Shares held
- 80.9M
- +2.12M (+2.7%) vs. Q2 2025
- Total value
- $4.58B
- +$1.14B (+33.2%) vs. Q2 2025
- New holders
- 40
- 81 more added
- Sold out
- 37
- 54 more reduced
3 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KYMR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 276 | $11.1B |
| Q1 2026 | 256 | $8.01B |
| Q4 2025 | 255 | $6.99B |
| Q3 2025 | 210 | $4.58B |
| Q2 2025 | 210 | $3.44B |
| Q1 2025 | 174 | $2.00B |
| Q4 2024 | 181 | $2.89B |
| Q3 2024 | 176 | $3.27B |
| Q2 2024 | 157 | $2.01B |
| Q1 2024 | 164 | $2.70B |
| Q4 2023 | 137 | $1.54B |
| Q3 2023 | 122 | $797.2M |
| Q2 2023 | 129 | $1.34B |
| Q1 2023 | 127 | $1.68B |
| Q4 2022 | 121 | $1.40B |
| Q3 2022 | 128 | $1.15B |
| Q2 2022 | 101 | $973.6M |
| Q1 2022 | 126 | $1.93B |
| Q4 2021 | 128 | $2.76B |
| Q3 2021 | 115 | $2.04B |
| Q2 2021 | 110 | $1.29B |
| Q1 2021 | 97 | $887.2M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Kymera Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Siren, L.L.C. | 3,428,150 | $194.0M | 7.59% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,365,448 | $247.1M | 0.00% | +217,188+5.2% | Added |
| Atlas Venture Life Science Advisors, LLC | 4,896,462 | $277.1M | 36.82% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 5,097,378 | $288.5M | 0.03% | −1,761,824−25.7% | Reduced |
| Wellington Management Group LLP | 5,195,691 | $294.1M | 0.05% | −176,370−3.3% | Reduced |
| Vanguard Group Inc | 5,421,722 | $306.9M | 0.00% | −198,126−3.5% | Reduced |
| BVF Inc | 5,502,710 | $311.5M | 12.63% | 00.0% | Unchanged |
| FMR LLC | 5,879,611 | $332.8M | 0.02% | +447,617+8.2% | Added |
| Avoro Capital Advisors LLC | 6,350,000 | $359.4M | 4.65% | −205,555−3.1% | Reduced |
| Baker Bros. Advisors LP | 6,651,429 | $376.5M | 2.72% | 00.0% | Unchanged |
| Redmile Group, LLC | 0 | $0 | 0.00% | −803,289−100.0% | Sold out |
| Suvretta Capital Management, LLC | 0 | $0 | 0.00% | −275,000−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −162,315−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −100,997−100.0% | Sold out |
| AXA S.A. | 0 | $0 | 0.00% | −90,971−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −85,000−100.0% | Sold out |
| Weiss Asset Management LP | 0 | $0 | 0.00% | −50,787−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Skandinaviska Enskilda Banken AB (publ) | 0 | $0 | 0.00% | −38,141−100.0% | Sold out |
| Royce & Associates LP | 0 | $0 | 0.00% | −33,797−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −28,906−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −21,600−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −13,366−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −11,546−100.0% | Sold out |
| Clear Harbor Asset Management, LLC | 0 | $0 | 0.00% | −11,194−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −11,107−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −10,850−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,362−100.0% | Sold out |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Mach-1 Financial Group, Inc. | 0 | $0 | 0.00% | −7,594−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −6,600−100.0% | Sold out |
| Inceptionr LLC | 0 | $0 | 0.00% | −6,468−100.0% | Sold out |
| Fieldview Capital Management, LLC | 0 | $0 | 0.00% | −5,929−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −5,882−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −5,661−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −5,289−100.0% | Sold out |
| Oxford Asset Management LLP | 0 | $0 | 0.00% | −4,598−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −4,344−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −2,664−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −2,595−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −1,664−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −334−100.0% | Sold out |
| Kestra Investment Management, LLC | 0 | $0 | 0.00% | −199−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −76−100.0% | Sold out |
| Accent Capital Management, LLC | 0 | $0 | 0.00% | −62−100.0% | Sold out |
| Sierra Ocean, LLC | 0 | $0 | 0.00% | −28−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| Norges Bank | – | – | – | – | Not filed |
| Keudell/Morrison Wealth Management | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |